Going Public: Managing Your Time, Money, and Expectations

  • Thursday June 27th, 11:30 AM- 12:20 PM

    Companies are well aware of the compliance costs associated with entering the public markets. Congress, too, has noticed, as evidenced by the recent passing of the JOBS Act – which broadens alternative methods to go public that can be significantly cheaper. Most importantly, the true ‘cost’ of becoming public is not only measured in dollars. Going public – and remaining operational and healthy – requires significant manpower and resources. The real cost of going public factors in the energy it takes to remain compliant, and the commitment to transparency. A company faces three main operational issues when exploring public markets:

    • Can the company allocate enough funds for initial costs to go public? Can the company foresee enough revenue to stay listed?
    • Does increased access to capital through public markets justify the daunting compliance and transparency commitment?
    • Which listing will guarantee sustainability and growth with appropriate resources available?


    This workshop, led by a respected advisor in bringing companies public, will focus on the financial and non-financial implications of entering the public markets.

    Hosted by EisnerAmper


    Pennett_John_newJohn Pennett, Partner-in-Charge of Life Sciences and Technology Groups, Eisner Amper, has more than 25 years of public accounting experience with a strong emphasis on public and private life sciences companies.  He is the publisher of Catalyst, a magazine focused solely on issues related to life sciences and pharmaceutical companies.  John also serves on the firm’s Public Companies Group. John is a member of the American Institute of Certified Public Accountants (AICPA) and New Jersey Society of Certified Public Accountants (NJSCPA), where he serves on the Cooperation with Bankers Committee.  He is also a member of BioNJ, where he is co-chair of the CFO Committee; New Jersey Technology Council (NJTC); Pennsylvania Bio; and the Accounting Advisory Board of the Rutgers University School of Business.  In addition, John is on the advisory board of the Commercialization Center for Innovative Technologies (CCIT) and the Business Development Incubator at New Jersey City University (NJCU).  He is a graduate of Rutgers University and previously worked as audit partner for an international accounting and consulting firm.

    Barbara_WoodBarbara Wood, Principal, Wood Legal, has been practicing law since her graduation from Columbia Law School in 1987. Currently, through Wood Legal, she advises individuals and small companies on a variety of corporate, commercial and M&A matters, such as contract drafting and negotiation, and entity formation, structuring and financing, with a particular focus on the biotechnology industry.  Prior to forming Wood Legal in 2011, Barbara was Senior Vice President, General Counsel and Secretary at OSI Pharmaceuticals, Inc., a publicly-traded mid-cap biotechnology company which was acquired by Japan-based pharmaceutical company, Astellas Pharma, for $4 billion in mid 2010. During her 10 years with OSI, Barbara built for OSI’s operations in the US and the UK (Oxford) not only the legal department but also the intellectual property (IP), corporate compliance and government affairs functions. At the time of the acquisition by Astellas, these departments were comprised of approximately 25 employees. Barbara earned her law degree from Columbia Law School where she was a Harlan Fiske Stone Scholar. She completed her undergraduate work at Connecticut College where she double-majored in classics and economics. She served as a member of the Board of Directors of the New York Biotechnology Association for many years.

    Chris_Schnittker G&A-19Christopher P. Schnittker, CPA, Senior Vice President and Chief Financial Officer, Echo Therapeutics, joined Echo Therapeutics, Inc., a NASDAQ-traded medical device company based in Philadelphia, in May 2011 as its Chief Financial Officer and later added the title of Senior Vice President in June 2012. Prior to joining Echo, Mr. Schnittker was the Vice President – Administration, Corporate Secretary and Chief Accounting Officer of Soligenix, Inc., an OTC Bulletin Board-traded biotechnology company developing small molecule pharmaceutical products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents, from July 2009 to April 2011. Prior to joining Soligenix, Mr. Schnittker was the Vice President and Chief Financial Officer of VioQuest Pharmaceuticals, an OTC Bulletin Board-traded biotechnology company targeting both the molecular basis of cancer and side effects of treatment based in Basking Ridge, NJ, from July 2008 until its dissolution in October 2009. Mr. Schnittker has also held previous management positions in accounting, reporting, finance and auditing at GSI Commerce (sold to eBay in a transaction valued at $2.4 billion), Rhône-Poulenc Rorer (now Sanofi Aventis), and Price Waterhouse (now PricewaterhouseCoopers). Mr. Schnittker received his B.A. degree in Economics and Business, with a concentration in Accounting, from Lafayette College and is a Certified Public Accountant fully licensed in the State of New Jersey. He grew up in Princeton, NJ and now lives just outside of Philadelphia, PA.

    Additional panelists to be named in the coming weeks.


  • Conference Info:


    Date: June 26-27, 2013
    Location: The Metropolitan Club, New York City

    Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.

    View the Schedule!

    View the Agenda!